Los Angeles - 
(NewMediaWire) - May 27, 2021 - The Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of NGM
Biopharmaceuticals, Inc. (“NGM” or “the
Company”) (NASDAQ: NGM) for violations of the securities laws.
The investigation focuses on whether the Company
issued false and/or misleading statements and/or failed to disclose information
pertinent to investors. NGM announced on May 24, 2021, that it would be
abandoning liver disease treatment candidate after failing to demonstrate
efficacy in its Phase 2 study. According to the Company, "The 24-week
Phase 2b ALPINE 2/3 was an equally randomized, double-blind, placebo-controlled
study that assessed the efficacy, safety and tolerability of 0.3 mg, 1 mg and 3
mg doses of aldafermin once-daily subcutaneous injections compared to placebo.
The study did not meet its primary endpoint evaluating a dose response showing
improvement in liver fibrosis by >1 stage with no worsening of NASH at week
24 (p=0.55), analyzed using a dose response-driven statistical analysis plan
(Multiple Comparison Procedure Modeling, or MCP-Mod). The study did achieve
statistical significance versus placebo on certain secondary endpoints,
including NASH resolution (at the 3 mg dose) and multiple non-invasive measures
of NASH, including liver fat content reduction by MRI-PDFF, ALT, AST and Pro-C3
(at the 1 mg and 3 mg doses)." Based on this news, shares of NGM fell
almost 40% in intraday trading.
If you are a shareholder who
suffered a loss, click
here to participate.
We also encourage you to contact
Brian Schall of the Schall Law Firm, 2049
Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not
yet been certified, and until certification occurs, you are not represented by
an attorney. If you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.
310-301-3335
